KCNA3 and Lambert-Eaton myasthenic syndrome: A second drug, 4-AP, has been used in Lambert-Eaton myasthenic syndrome and multiple sclerosis and acts by blocking potassium channels, prolonging action potentials, and increasing neurotransmitter release at the neuromuscular junction.